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ABSTRACT The physiologic balance between the two reg-
ulatory subunit Isoforms, RI and RH, of cAMP-dependent
protein kinase is disrupted in cancer cells; growth arrest and
differentiation of maliant cells can be achieved when the
normal ratio of these intracellular signal transducers ofcAMP
is restored by the use of site-selective cAMP analogs. In this
study we evaluated the effects of the site-selective cAMP analog
8-chloroadenosine 3',5'-cyclic monophosphate (8-Cl-cAMP)
on clonogenic growth of blast progenitors from 15 patients with
acute myeloblastic leukemia and 3 patients affected by ad-
vanced myelodysplastic syndrome. Leukemic blast progenitors
undergo terminal divisions, giving rise to colonies in methyl-
cellulose. The self-renewal capacity of blast progenitors is
conversely reflected in a secondary methylcellulose assay after
exponential growth of clonogenic cells in suspension cultures.
In all the samples tested, 8-Cl-cAMP, at micromolar concen-
trations (0.1-50 IpM), suppressed in a dose-dependent manner
both primary colony formation in methylcellulose and the
recovery of clonogenic cells from suspension culture. Strik-
ingly, in the samples from the entire group of patients, 8-Cl-
cAMP was more effective in inhibiting the self-renewing do-
nogenic cells than the terminally dividing blast cells (P =
0.005). In addition, in four out of six cases studied, 8-Cl-cAMP
was able to induce a morphologic and/or immunophenotypic
maturation ofleukemic blasts. An evident reduction ofRI levels
in fresh leukemic cells after exposure to 8-Cl-cAMP was also
detected. Our results showing that 8-Cl-cAMP is a powerful
inhibitor of clonogenic growth ofleukemic blast progenitors by
primarily suppressing their self-renewal capacity indicate that
this site-selective cAMP analog represents a promising biolog-
ical agent for acute myeloblastic leukemia therapy in humans.
The progressive accumulation of leukemic cells in acute
myeloblastic leukemia (AML) is sustained by a small popu-
lation of leukemic blast progenitors (1, 2). Leukemic blast
progenitors, like normal hemopoietic stem cells, are able to
renew themselves and/or undergo terminal divisions giving
rise to nonrenewing end cells that, however, do not achieve
morphological maturity (2, 3). The self-renewal capacity of
blast progenitors has been shown to be highly correlated with
clinical outcome in AML (4-6).
Currently, however, no means are available to distinguish
between the "determined" and "self-renewing" blast cells
on morphological, phenotypical, or molecular grounds. Mc-
Culloch and associates (2, 7) have developed the only culture
method to date that is able to make an operational distinction
between the self-renewal and postdeterministic mitoses. The
culture method consists of two different assays: (i) direct
semisolid medium (methylcellulose) cloning and (ii) a 7-day
liquid culture, after which cells are replated in a methylcel-
lulose cloning assay. Conclusive evidence has been provided
that, during the liquid culture, self-renewing clonogenic cells
increase exponentially and are selected against determined
but still dividing blasts, so that they can be specifically
assayed in the subsequent cloning assay (8). Thus, in the
primary methylcellulose cloning, determined clonogenic
cells can be enumerated, while the secondary cloning fol-
lowing liquid culture allows the quantitations of self-renewing
clonogenic cells (8, 9). Most importantly, this method rep-
resents a predictive in vitro model for evaluating the thera-
peutic efficacy of anticancer agents in AML (1, 2, 6, 7). In
vitro evaluation of self-renewing clonogenic cells and their
inhibition by different drugs, as described by McCulloch and
associates (2, 4), have been significantly associated with the
clinical outcome and response to therapeutic agents admin-
istered in vivo to AML patients (2, 4, 6, 7). To eradicate
AML, it is therefore important to search for antitumor agents
that can inhibit not only terminal divisions, like most cyto-
toxic drugs (10, 11), but also can inhibit self-renewal of
leukemic blast progenitors.
Previous studies have shown that site-selective cAMP
analogs are able to induce potent growth inhibition and
differentiation in a broad spectrum of cancer cells (12),
including human leukemia cells (13, 14). Site-selective cAMP
analogs bind selectively to sites present on each of the two
regulatory subunits of the cAMP-dependent protein kinases,
type I (RI) and type II (RII) (15-17), respectively. Inhibition
of cancer cell growth by 8-chloroadenosine 3',5'-cyclic
monophosphate (8-Cl-cAMP), the most potent site-selective
cAMP analog, is accompanied by a reduction in the levels of
the RI cAMP receptor protein and an increase in RII levels
(13, 14, 18). Accordingly, an accumulation of the RI subunit
has been associated with growth stimulation and neoplastic
transformation, whereas an increase in the RII subunit has
been related to growth arrest and cell differentiation (12, 19,
20). Site-selective cAMP analogs represent a promising ad-
ditional class of antitumor agents; however, their prospective
impact in the therapy of human leukemias remains to be fully
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elucidated. In the present study we have analyzed the effects
of 8-Cl-cAMP on blast progenitors-from AML patients.
MATERIALS AND METHODS
Leukemic Cells. Peripheral blood samples were obtained
after informed consent from 15 patients with AML at the time
of diagnosis. Bone marrow samples from 3 patients with
myelodysplastic syndrome were also studied. The diagnosis
was made according to the French-American-British (FAB)
criteria (21) (see Table 1) and confirmed by cytochemistry
and flow cytometry immunophenotyping. Ficoll/Hypaque-
isolated blast cells were T-cell-depleted as described (22) and
either cultured immediately or cryopreserved in liquid nitro-
gen.
Culture Methods. Methylcellulose clonogenic assays and
suspension cultures were performed according to McCulloch
(2), Wang and McCulloch (10), and Nara et al. (23). Cells (1
x 106/ml) were incubated for 48 hr in Dulbecco's modified
Eagle's medium containing 20%o (vol/vol) heat-inactivated
fetal calf serum and 10%o medium conditioned by the 5637 cell
line (5637-CM) (24) as a source ofgrowth factors. All samples
showed >90% blast cells following preculture, except for
those from patients 1, 7, and 16, in which 63%, 68%, and 70%o
blasts were detected, respectively. For the methylcellulose
blast colony assay (10, 25), 2 x 105 cells were suspended in
1 ml of Dulbecco's modified Eagle's medium containing 20%o
fetal calf serum, 10% 5637-CM, and 0.8% methylcellulose
along with increasing concentrations (1-50 ,uM) of 8-Cl-
cAMP (Division of Cancer Treatment, National Cancer In-
stitute, National Institutes of Health) and cultured in 100-pl
aliquots in 96-well flat-bottomed microplates. After 7 days of
incubation, aggregates with >20 cells were scored as colo-
nies, and the results were expressed as a plating efficiency in
methylcellulose (PEmc). Eight to 10 replicates were used to
determine PEmc.
For suspension cultures, cells (2 x 105/ml) were incubated
in the presence of 10% 5637-CM and increasing concentra-
tions of 8-Cl-cAMP in six-well microplates. After 7 days,
nonadherent cells were harvested, counted, washed twice in
Dulbecco's modified Eagle's medium to remove 8-Cl-cAMP,
and replated in analog-free methylcellulose as described
above. Colonies grown in this assay yielded a plating effi-
ciency after suspension culture (PEs). The number of self-
renewing clonogenic cells was expressed as the number of
colonies (PEs) adjusted for the number of nonadherent cells
present in 1 ml of suspension culture (clonogenic cell recov-
ery) (2, 10, 23).
Simple negative survival curves were computed by linear
regression by comparing the number of clonogenic cells,
derived from suspension culture or methylcellulose culture at
each dose of 8-Cl-cAMP, with controls. From these curves,
the doses required to reduce survival to 10% (D10) and 50%
(D50) of the control, respectively, were obtained.
Survival curves were also obtained from experiments
performed either without growth factors or by using a serum-
free medium (26) or medium supplemented with serum-free
5637-CM (27). The effects of such culture manipulations were
inferred from the multiple parameters obtained from meth-
ylcellulose or suspension cultures and were conveniently
integrated in a star diagram (28, 29).
Morphological Studies and Cell Surface Antigen Analysis. In
selected cases (cases 6, 9, 11, 12, 17, and 18), blast cell
morphology and immunophenotypic changes were assessed
by May-Grunwald-Giemsa staining of cytospin preparations
and flow cytometry analysis of 7-day-old liquid cultures
performed in the presence of 8-Cl-cAMP (1-50 ,uM). Modu-
lation of cell surface antigens (CD11b/Mol, CD13/My7,
CD14/My4, CD33/My9, CD71/anti-transferrin receptor,
and CD15/OKM15) was analyzed by a FACScan cytofluo-
rograph (Becton Dickinson) as described (30).
Photoafflnity Labeling of cAMP Receptor Proteins. Prepa-
ration of cell extracts and photoactivated incorporation of
8-azidoadenosine 3',5'-cyclic [32P]monophosphate followed
the method previously described (13, 18). The samples con-
taining 25-50 Ag of protein were subjected to electrophoresis
in 0.05% SDS/12% polyacrylamide gels (18), and the sepa-
rated proteins were transferred to nitrocellulose sheets (18).
The sheets were air dried and exposed to Kodak XAR film
overnight at -20'C.
Statistical Analysis. Mean values, standard errors (SE), and
95% confidence intervals for the means were computed (31).
Statistical differences between means were tested by Stu-
dent's t test (31). D10 and D50 values for 8-Cl-cAMP were
determined from the slope of negative exponential dose-
response survival curves computed by linear regression and
were compared as described (31).
RESULTS
Effects of 8-Cl-cAMP on Self-Renewal and Terminal Divi-
sions of Leukemic Blast Progenitors. Representative dose-
response survival curves of leukemic blast progenitors are
shown in Fig. 1. Exposure to 8-Cl-cAMP (0.1-50 uM) re-
sulted in a dose-dependent inhibition ofblast cells both in the
primary methylcellulose cloning and the secondary cloning
after suspension culture. Survival curves are depicted by
standard slope parameters D10 and D50, which represent the
concentration of 8-Cl-cAMP required to reduce survival to
10% and 50o ofcontrols, respectively (Table 1). In blast cells
from all patients, 8-Cl-cAMP showed a striking inhibitory
effect on colony growth after suspension culture. D10 and D50
mean values in methylcellulose were higher (P = 0.005) than
in suspension (Table 1). According to their patterns of
response to 8-Cl-cAMP, we divided our samples into three
subgroups operationally termed A, B, and C (Fig. 1). These
subgroups were mathematically defined by statistically sig-
nificant differences between D10 (or D50) mean values in
methylcellulose and in suspension. In each of the three
groups, 95% confidence intervals were never overlapping
(data not shown). These subsets, however, did not correlate
with the FAB classification or with the clinical state of
patients and more likely reflect a biological heterogeneity
within the AML group (Table 1) (2). In the first subset (group
A; patients 1, 6, 10, 13, and 15), clonogenic cells were
strongly suppressed in suspension compared with methylcel-
lulose cultures; they exhibited the maximal difference be-
tween Dio (or D50) mean values in methylcellulose and in
suspension. In the second group (group B; patients 2, 3, 4, 14,
and 17), both clonogenic cells in suspension and in methyl-
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FIG. 1. Representative dose-survival curves of leukemic blast
progenitors exposed to increasing concentrations of 8-Cl-cAMP in
methylcellulose (0) and suspension (m) cultures from patients 6 (A),
2 (B), and 9 (C). The negative exponential dose-response survival
curves are drawn by linear regression and may be described by a
single slope parameter [i.e., the D10 or D50 value (see Materials and
Methods)]. Comparisons between linear regression curves obtained
in methylcellulose (meth) and in suspension (susp) cultures reached
statistical significance (P < 0.05) in A and B.
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Table 1. Clinical characteristic and response to 8-Cl-cAMP of blast cell progenitors from patients
with AML and myelodysplastic syndrome
Patient Diagnosis Blasts at D1o, AM D5o, .M
no. (FAB) diagnosis, % MC Suspension MC Suspension
1 RAEB-T 25 100.00 35.95 40.00 10.95
2 Ml 90 16.81 5.94 4.91 1.83
3 M2 54 31.66 17.33 9.34 5.19
4 Ml 85 22.52 9.55 6.7 3.0
5 MO 90 8.15 10.15 2.00 2.75
6 M2 63 65.00 3.50 19.40 1.10
7 RAEB-T 27 0.50 0.10
8 M4 40 7.82 2.31
-
9 Ml 95 3.64 2.50 1.10 0.69
10 Ml 92 37.37 0.03 10.71 0.01
11 M4 94 2.14 0.88 0.65 0.27
12 M5 51 9.63 2.74 2.82 0.83
13 M5 90 89.00 4.00 26.60 1.80
14 MO 80 50.00 28.55 15.00 8.43
15 M2 86 38.55 3.74 11.41 1.06
16 RAEB-T 25 1.30 6.50 0.44 1.80
17 M2 95 27.85 2.50 8.25 0.75
18 M4 93 6.65 2.00
A statistical analysis was performed, excluding patients 7, 8, and 18. In the whole group of patients,
Dio mean values ± SE in methylcellulose and in suspension culture were 33.6 ± 7.9 AM and 8.9 ± 2.7
ELM, respectively (P = 0.005). Similarly, D50 mean values ± SE were 10.6 ± 2.8 AM in methylcellulose
and 2.7 ± 0.8,M in suspension (P = 0.005). RAEB-T, refractory anemia with excess of blasts; MC,
methylcellulose culture. Data are expressed as the mean of 8-10 replicate microwells. -, No growth
was observed both in controls and in 8-Cl-cAMP-treated dishes after suspension culture.
cellulose cultures were inhibited by 8-Cl-cAMP, but a more
marked effect in suspension was observed. 8-Cl-cAMP dose-
survival curves of blast progenitors from these two groups
were similar to those obtained with ara-C, a cytotoxic drug
previously shown primarily to suppress self-renewal ofAML
progenitors (7). In the third group (group C; patients 5, 9, 11,
12, and 16), clonogenic cells recovered in suspension or
grown in semisolid medium were similarly suppressed, as
described for the anticancer drugs adriamycin and 4-hydro-
peroxycyclophosphamide (7, 11). Finally, in two patients
from this group, culture conditions favoring self-renewal
rather than terminal divisions resulted in an increased sen-
sitivity of leukemic progenitors to 8-Cl-cAMP in suspension
(see below).
Effects of Culture Conditions Favoring Self-Renewal or
Terminal Divisions of Leukemic Blast Progenitors on Sensitiv-
ity to 8-Cl-cAMP. Star diagrams and 8-Cl-cAMP dose-
survival curves after suspension culture of blast cells from
two patients cultured in conditions favoring self-renewal or
terminal divisions are shown in Fig. 2. In case 9 (Fig. 2A
Inset), serum-containing medium strongly enhanced blasts'
self-renewal, as evidenced by the star diagram displaying
high values for the self-renewal-related parameters PEs and
clonogenic cell recovery. Conversely, in serum-free cultures,
self-renewal-related functions were decreased and terminal
divisions were favored, as shown by an increased PEmc.
Dose-survival curves (Fig. 2A) showed that blast cells from
patient 9 were more sensitive to 8-Cl-cAMP under culture
conditions where self-renewal mitoses are favored [serum-
containing medium (SCM) vs. serum-free medium (SFM)] (P
< 0.001). For blast cells from patient 5 (Fig. 2B Inset),
analysis of star diagrams showed that growth in the absence
of growth factors was characterized by higher self-renewal
values (PEs and clonogenic cell recovery) compared with
cultures with serum-free 5637-CM in which a low PEs was
detected. Again, survival curves (Fig. 2B) were consistent
with the star diagrams, and blasts appeared more sensitive to
8-Cl-cAMP in suspension culture in the absence of growth
factors [no growth factors (GFs) vs. 5637-CM] (P < 0.001).
Effects of 8-Cl-cAMP on Morphology and Surface Pheno-
type of Fresh AML Cells. To investigate the relationship
between inhibition of colony growth and the capability of
8-Cl-cAMP to promote leukemia cell differentiation, exper-
iments were performed using blast cells from selected pa-
tients (patients 6, 9, 11, 12, 17, and 18) exhibiting a different
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FIG. 2. Dose-survival curves for recovery of clonogenic cells
from suspension cultures of blast progenitors from patients 9(A) and
S (B) exposed to 8-Cl-cAMP under different growth conditions.
Dashed lines and circles refer to experiments carried out in serum-
free medium (SEM) in A or in the presence of 5637-CM in B;
continuous lines and squares indicate experiments performed in
serum-containing medium (SCM) in A and in the absence of any
source of growth factors (no GFs) in B. (Insets) For each panel, two
superimposed star diagrams are included; each axis of the star
diagram is scaled for one of the growth parameters that characteinze
blast population: the upper vertical axis reresents the nonadherent
cell number x 10iper ml after suspension culture, the lowe ertical
axis represents clonogenic cell recovery (cell number x 103 per ml)
from liquid cultures, the right horizontal axis is PEmc (colonies per
2 x1so cells), and the left horizontal axis is PEs (colonies per 2 x
105 cells). According to Miyauchi et al. (28, 29), axes have been
chosen so that a movement to the left and down indicates a shift
toward self-renewal mitoses while a movement to the right and up
suggests that t aerminal divisions are favored.
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sensitivity to 8-Cl-cAMP. Blasts from patients 6, 9, 11, and
18, exposed for 7 days to 8-Cl-cAMP (1-50 AuM), did not show
any significant morphological changes when compared with
controls. In contrast, the blast cells from two patients (pa-
tients 12 and 17) were induced to differentiate by 8-Cl-cAMP
as shown by morphological changes consistent with granu-
locytic (case 17; Fig. 3 A-D) or monocytic (case 12; Fig. 3 E
and F) differentiation and by a striking upregulation of the
mature granulocytic (CD15) and monocytic (CD14) antigens
(Fig. 3 G and H). A significant reduction in the expression of
the early myeloid antigen CD33 and of the proliferation-
associated transferrin receptor (CD71) was also observed in
both cases. Interestingly, in cells from patients 9 and 18,
exposure to 8-Cl-cAMP, although not inducing a morpholog-
ical maturation, resulted in a significant downregulation of
CD33 and CD71 antigens.
Effects of8-Cl-cAMP and RI andRHcAMP Receptor Levels
of Fresh Blast Cells from AML Patients. To examine whether
the growth inhibitory effect of 8-Cl-cAMP observed in the
AML blast cells correlates with the modulation of cAMP
receptor proteins (RI and RII) in the leukemia cells, we
determined the receptor levels in these cells by photoaffinity
labeling with 8-azidoadenosine 3',5'-cyclic [32P]monophos-
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FIG. 3. Morphological and immunophenotypical changes in-
duced by 8-Cl-cAMP on fresh AML cells. (A-D) Blast cells from
patient 17 (FAB-M2) cultured for 7 days in the absence (A and B) or
in the presence (C and D) of 20 ,uM 8-Cl-cAMP. (E and F) Blast cells
from patient 12 (FAB-M5) cultured for 7 days in the absence (E) or
in the presence (F) of 20 jLM 8-Cl-cAMP. Cytospin preparations of
cultured cells were stained with May-Grunwald-Giemsa for mor-
phological assessment. (A and B, x950; C and D, x475; E and F,
x1190.) (G and H) Overlay histograms of fluorescence intensity
showing the upregulation of differentiation antigens CD15 (G) and
CD14 (H) on blast cells from patients 17 (G) and 12 (H) following
exposure for 7 days to 20 ,uM 8-Cl-cAMP. The x axis indicates
decades of log fluorescence intensity, and the y-axis indicates the
number of cells. Flow cytometry data were generated by means of a
LYSIS II software (Becton Dickinson).
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FIG. 4. Effect of 8-Cl-cAMP on cAMP receptor levels of fresh
blast cells from three AML patients: patient 1 (RAEB-T), patient 2
(FAB-Ml), and patient 3 (FAB-M2). Preparation of cell extracts and
photoaffinity labeling with 8-azidoadenosine 3',5'-cyclic [32P]mono-
phosphate followed the methods described in Materials and Meth-
ods. Lanes 1, 3, and 5, untreated control cells (patients 1-3); lanes
2, 4, and 6, cells treated for 3 days with 5 AuM 8-Cl-cAMP (patients
1-3); lanes R1. and RIla, rabbit skeletal muscle RIa and bovine heart
muscle RILa, respectively.
phate followed by SDS/PAGE. As shown in Fig. 4, untreated
control cells from three AML patients each exhibited a major
band of48-kDa, which comigrated with rabbit skeletal muscle
RI., that we refer to as RI,. Minor bands of 65-, 44-, and
37-kDa proteins were also identified; the 44- and 37-kDa
bands, which could be displaced by the addition ofa 1000-fold
excess of unlabeled cAMP, may represent proteolytically
degraded cAMP-binding proteins, whereas the 65-kDa pro-
tein band, which shows partial displacement by excess cAMP
and comigrates with bovine serum albumin, exhibits nonspe-
cific cAMP binding. Treatment ofthese cells with 8-Cl-cAMP
(5 ,gM) for 3 days resulted in an almost complete abolishment
of RI. and a decrease in the minor cAMP-binding proteins.
However, a decrease was not observed in the 65-kDa protein,
the nonspecific binding protein (Fig. 4). RII cAMP-binding
protein was not detected in either untreated control cells or
in cells treated with 8-Cl-cAMP (Fig. 4).
DISCUSSION
In the present study, we examined the ability of a site-
selective cAMP analog, 8-Cl-cAMP, to affect both terminal
divisions (clonogenic growth in methylcellulose) and self-
renewal capacity (clonogenic growth after suspension cul-
ture) of AML blast cell progenitors. 8-Cl-cAMP was highly
effective in suppressing leukemic blasts' colony formation in
a dose-dependent manner. In addition, in 10 of 15 samples,
8-Cl-cAMP was more effective in inhibiting clonogenic cells
grown in suspension than primary colonies grown in meth-
ylcellulose. From these data, it can be concluded that 8-Cl-
cAMP is a powerful inhibitor of blast cell growth, primarily
affecting its self-renewal capacity.
The mechanisms underlying the preferential suppression of
the self-renewal capacity by 8-Cl-cAMP remain to be deter-
mined, and at least two possibilities must be considered. One
is that self-renewal of blast progenitors is directly suppressed
by 8-Cl-cAMP. High levels of RI cAMP receptor proteins
have been associated with active cell growth, neoplastic
transformation, and early stages of differentiation (12, 20, 32,
33), whereas a RI decrease and/or increase in RII correlate
with growth arrest and maturation in a variety of cell types,
including human leukemic cells (13, 14). It is conceivable that
an actively self-renewing subpopulation of blast progenitors
may display higher levels ofRI subunits compared with blasts
committed to terminal divisions, resulting in greater sensi-
tivity to 8-Cl-cAMP. Whether changes in culture microenvi-
ronment that modify the balance between self-renewal and
terminal divisions would alter RI and RII relative levels in
fresh AML blasts remains to be determined. The marked
alteration in sensitivity of leukemic cells to 8-Cl-cAMP that
we observed after manipulation of culture conditions in two
Medical Sciences: Pinto et al.
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AML samples strongly supports such a view (Fig. 2). The
growth-inhibitory potency of site-selective cAMP analogs is
dependent on RI and RII relative levels in target cells (12, 20,
32, 33). Our results have shown that RIE levels in fresh cells
from AML patients are dramatically decreased by exposure
to 8-Cl-cAMP. Another explanation for our results is that
8-Cl-cAMP might induce terminal divisions and differentia-
tion of blast progenitors, with a consequent reduction of their
self-renewal capacity. Such a possibility is in agreement with
the demonstration that site-selective cAMP analogs, includ-
ing 8-Cl-cAMP, are able to induce morphologic and/or func-
tional differentiation of the human leukemic cell lines HL60
(13) and K562 (14). In the present study, blast cells from two
of six patients were induced to differentiate by 8-Cl-cAMP,
as evaluated by morphological and immunophenotypical
changes, and in two other cases cell surface modifications
compatible with a shift toward a mature phenotype were
obtained. In operational terms, therefore, 8-Cl-cAMP, like
any biological agent able to induce the loss of self-renewal in
leukemic cells (without causing acute cell killing), can be
considered a "differentiation inducer" even if not all mature
phenotypic markers are acquired as a result of its action. As
a matter of fact, the majority of so-called differentiation
inducers, including those currently adopted in clinical trials,
can cause a cytological and phenotypical maturation in a
relatively low percentage of fresh AML cells in vitro (34)
while inducing an almost total abolishment of the clonogenic
capacity of the whole cell population. Thus, the noncytolog-
ically mature cells are, notwithstanding, "functionally dif-
ferentiated" as long as they lack the stem cell property of
self-renewal. From our data it clearly appears that 8-Cl-
cAMP induced functional differentiation (i.e., the loss of
self-renewal) in almost all blast cell progenitors in all the
samples; in addition, it further pushed the differentiation
program (i.e., acquisition of cytological and/or surface mark-
ers) in four of six samples tested (i.e., 66%). On the other
hand, it is most probable that AML cells are rendered by
8-Cl-cAMP sensitive to other differentiation signals (i.e.,
hemopoietic growth factors) and that the combination of
more than one factor is required to bring about the entire
differentiation program in AML cells.
The preferential inhibition of the self-renewal capacity of
AML progenitors by 8-Cl-cAMP demonstrated by us in the
present study suggest another approach in AML therapy.
Self-renewal capacity of leukemic cells is strictly correlated
with the clinical outcome in AML (4-6); patients in which
blast progenitors display a high self-renewal capacity in vitro
have a low probability of achieving complete remission and
show a low survival rate (4-6). The availability of biological
agents inhibiting the self-renewal capacity of leukemic stem
cells provides a very useful tool for AML therapy, since a
cure in these patients may be achieved only if blasts' self-
renewal is completely abolished. We have shown here that
8-Cl-cAMP, at micromolar concentrations, provokes a dras-
tic suppression ofAML clonogenic cells by primarily affect-
ing their self-renewal capacity. Our data strongly indicate
that 8-Cl-cAMP may represent a promising additional agent
for AML therapy in humans.
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